Drug Trial Radar · NCT07700667
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Aug 13, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability and preliminary antitumor activity of SKB500 combinations in patients with Esophageal Squamous Cell Carcinoma. The study is divided into two parts: the safety run-in phase and the cohort expansion phase.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
SKB500Drug
SKB500 will be administered as an intravenous infusion(IV), every 3 weeks on Day 1 of each 21-day cycle.
TislelizumabDrug
Tislelizumab will be administered as an intravenous infusion(IV) every 3 weeks on Day 1 of each 21-day cycle .
CisplatinDrug
Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle.
5 - FUDrug
5-FU will be administered as an intravenous infusion(IV) every 3 weeks on Day 1-5 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: up to 24 months
- Incidence and severity of adverse events (AEs) and serious adverse event(SAEs)Time frame: up to 24 months
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Jilin Cancer Hospital
Changchun, China · Recruiting
Chengdu Fifth People's Hospital
Chengdu, China · Recruiting
Sichuan Cancer Hospital & Institute
Chengdu, China · Recruiting
West China Hospital, Sichuan University
Chengdu, China · Recruiting
Chongqing University Three Gorges Hospital
Chongqing, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Ha’erbin, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Yunnan Cancer Hospital
Kunming, China · Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, China · Recruiting
Jiangsu Cancer Hospital
Nanjing, China · Recruiting
Jiangsu Province Hospital
Nanjing, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, China · Recruiting
Cancer Hospital of Shantou University Medical College
Shantou, China · Recruiting
Cancer Hospital of Dalian University of Technology
Shenyang, China · Recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China · Recruiting
Shiyan Renmin Hospital
Shiyan, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China · Recruiting
Yichang Central People's Hospital
Yichang, China · Recruiting
Henan Cancer Hospital
Zhengzhou, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.